204 related articles for article (PubMed ID: 15809523)
1. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.
Stemmler J; Mair W; Stauch M; Papke J; Deutsch G; Abenhardt W; Dorn B; Kentenich C; Malekmohammadi M; Jackisch C; Leinung S; Brudler O; Vehling-Kaiser U; Stamp J; Heinemann V
Oncology; 2005; 68(1):71-8. PubMed ID: 15809523
[TBL] [Abstract][Full Text] [Related]
2. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
Ford HE; Yap YS; Miles DW; Makris A; Hall M; Miller L; Harries M; Smith IE; Johnston SR
Cancer Chemother Pharmacol; 2006 Dec; 58(6):809-15. PubMed ID: 16528527
[TBL] [Abstract][Full Text] [Related]
4. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.
Montemurro F; Choa G; Faggiuolo R; Donadio M; Minischetti M; Durando A; Capaldi A; Vietti-Ramus G; Alabiso O; Aglietta M
Oncology; 2004; 66(1):38-45. PubMed ID: 15031597
[TBL] [Abstract][Full Text] [Related]
6. A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer.
Hosonaga M; Ito Y; Tokudome N; Takahashi S; Iwase T; Hatake K
Breast Cancer; 2012 Oct; 19(4):329-34. PubMed ID: 21863309
[TBL] [Abstract][Full Text] [Related]
7. Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer.
Stemmler HJ; Harbeck N; Gröll de Rivera I; Vehling Kaiser U; Rauthe G; Abenhardt W; Artmann A; Sommer H; Meerpohl HG; Kiechle M; Heinemann V
Oncology; 2010; 79(3-4):197-203. PubMed ID: 21358207
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
Im SA; Kim SB; Lee MH; Im YH; Lee KH; Song HS; Lee MA; Lee J; Lee NS; Ham HS; Kim TY; Park YH; Lee KE; Kim KW; Seo JH; Lee SN; Hong YS; Bang YJ; Kim WK; Park HS
Oncol Rep; 2005 Aug; 14(2):481-7. PubMed ID: 16012734
[TBL] [Abstract][Full Text] [Related]
9. Protracted administration of weekly docetaxel in metastatic breast cancer.
Kuroi K; Bando H; Saji S; Toi M
Oncol Rep; 2003; 10(5):1479-84. PubMed ID: 12883727
[TBL] [Abstract][Full Text] [Related]
10. Factors predicting docetaxel-related toxicity: experience at a single institution.
Massacesi C; Marcucci F; Rocchi MB; Mazzanti P; Pilone A; Bonsignori M
J Chemother; 2004 Feb; 16(1):86-93. PubMed ID: 15078005
[TBL] [Abstract][Full Text] [Related]
11. Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology.
Beuselinck B; Wildiers H; Wynendaele W; Dirix L; Kains JP; Paridaens R
Crit Rev Oncol Hematol; 2010 Jul; 75(1):70-7. PubMed ID: 19651523
[TBL] [Abstract][Full Text] [Related]
12. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
Schuette W; Nagel S; Blankenburg T; Lautenschlaeger C; Hans K; Schmidt EW; Dittrich I; Schweisfurth H; von Weikersthal LF; Raghavachar A; Reissig A; Serke M
J Clin Oncol; 2005 Nov; 23(33):8389-95. PubMed ID: 16293869
[TBL] [Abstract][Full Text] [Related]
13. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer.
Trent JC; Valero V; Booser DJ; Esparza-Guerra LT; Ibrahim N; Rahman Z; Vernillet L; Patel S; David CL; Murray JL; Cristofanilli M; Hortobagyi GN
Clin Cancer Res; 2003 Jul; 9(7):2426-34. PubMed ID: 12855614
[TBL] [Abstract][Full Text] [Related]
14. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T
Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.
Lee JL; Ryu MH; Chang HM; Kim TW; Yook JH; Oh ST; Kim BS; Kim M; Chun YJ; Lee JS; Kang YK
Cancer Chemother Pharmacol; 2008 Apr; 61(4):631-7. PubMed ID: 17520252
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD
Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236
[TBL] [Abstract][Full Text] [Related]
18. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.
Estévez LG; Cuevas JM; Antón A; Florián J; López-Vega JM; Velasco A; Lobo F; Herrero A; Fortes J
Clin Cancer Res; 2003 Feb; 9(2):686-92. PubMed ID: 12576436
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
Marty M; Cognetti F; Maraninchi D; Snyder R; Mauriac L; Tubiana-Hulin M; Chan S; Grimes D; Antón A; Lluch A; Kennedy J; O'Byrne K; Conte P; Green M; Ward C; Mayne K; Extra JM
J Clin Oncol; 2005 Jul; 23(19):4265-74. PubMed ID: 15911866
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
